These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 11408219)

  • 1. Identification of Proteus mirabilis mutants with increased sensitivity to antimicrobial peptides.
    McCoy AJ; Liu H; Falla TJ; Gunn JS
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2030-7. PubMed ID: 11408219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Release of the lipopolysaccharide deacylase PagL from latency compensates for a lack of lipopolysaccharide aminoarabinose modification-dependent resistance to the antimicrobial peptide polymyxin B in Salmonella enterica.
    Kawasaki K; China K; Nishijima M
    J Bacteriol; 2007 Jul; 189(13):4911-9. PubMed ID: 17483225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of polymyxins on the lipopolysaccharide-defective mutants of Proteus mirabilis.
    Kaca W; Radziejewska-Lebrecht J; Bhat UR
    Microbios; 1990; 61(246):23-32. PubMed ID: 2156134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of RppA in the regulation of polymyxin b susceptibility, swarming, and virulence factor expression in Proteus mirabilis.
    Wang WB; Chen IC; Jiang SS; Chen HR; Hsu CY; Hsueh PR; Hsu WB; Liaw SJ
    Infect Immun; 2008 May; 76(5):2051-62. PubMed ID: 18316383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic identification of genetic loci required for polymyxin resistance in Campylobacter jejuni using an efficient in vivo transposon mutagenesis system.
    Lin J; Wang Y; Hoang KV
    Foodborne Pathog Dis; 2009 Mar; 6(2):173-185. PubMed ID: 19105633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacterial modification of LPS and resistance to antimicrobial peptides.
    Gunn JS
    J Endotoxin Res; 2001; 7(1):57-62. PubMed ID: 11521084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
    Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
    J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteus mirabilis clinical isolate harbouring a new variant of Salmonella genomic island 1 containing the multiple antibiotic resistance region.
    Ahmed AM; Hussein AI; Shimamoto T
    J Antimicrob Chemother; 2007 Feb; 59(2):184-90. PubMed ID: 17114173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of UDP-glucose dehydrogenase and UDP-glucose pyrophosphorylase mutants of Proteus mirabilis: defectiveness in polymyxin B resistance, swarming, and virulence.
    Jiang SS; Lin TY; Wang WB; Liu MC; Hsueh PR; Liaw SJ
    Antimicrob Agents Chemother; 2010 May; 54(5):2000-9. PubMed ID: 20160049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteus mirabilis pmrI, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion.
    Jiang SS; Liu MC; Teng LJ; Wang WB; Hsueh PR; Liaw SJ
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1564-71. PubMed ID: 20123999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides.
    Campos MA; Vargas MA; Regueiro V; Llompart CM; Albertí S; Bengoechea JA
    Infect Immun; 2004 Dec; 72(12):7107-14. PubMed ID: 15557634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the PR mutant with the wild-type strain of proteus mirabilis brings insight into peroxide resistance factors and regulation of catalase expression.
    Andreoletti P; Franzetti B; Nussaume L; Andrieu JP; Gagnon J; Luche S; Rabilloud T; Jouve H
    Can J Microbiol; 2001 Feb; 47(2):130-8. PubMed ID: 11261492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
    Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
    Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decoration of Pasteurella multocida lipopolysaccharide with phosphocholine is important for virulence.
    Harper M; Cox A; St Michael F; Parnas H; Wilkie I; Blackall PJ; Adler B; Boyce JD
    J Bacteriol; 2007 Oct; 189(20):7384-91. PubMed ID: 17704225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of antibiotic resistance of rough and smooth Proteus mirabilis strains and influence of polymyxin E on their lipopolysaccharide composition.
    Kaca W; Ujazda E
    Acta Microbiol Pol; 1996; 45(2):161-8. PubMed ID: 8997693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human complement activation by smooth and rough Proteus mirabilis lipopolysaccharides.
    Kaca W; Arabski M; Fudała R; Holmström E; Sjöholm A; Weintraub A; Futoma-Kołoch B; Bugla-Płoskońska G; Doroszkiewicz W
    Arch Immunol Ther Exp (Warsz); 2009; 57(5):383-91. PubMed ID: 19707721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and genetic characterization of PmrA-regulated genes and genes involved in polymyxin B resistance in Salmonella enterica serovar typhimurium.
    Tamayo R; Ryan SS; McCoy AJ; Gunn JS
    Infect Immun; 2002 Dec; 70(12):6770-8. PubMed ID: 12438352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New aspects of RpoE in uropathogenic Proteus mirabilis.
    Liu MC; Kuo KT; Chien HF; Tsai YL; Liaw SJ
    Infect Immun; 2015 Mar; 83(3):966-77. PubMed ID: 25547796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activation by Proteus mirabilis negatively charged lipopolysaccharides.
    Kaca W; Literacka E; Sjöholm AG; Weintraub A
    J Endotoxin Res; 2000; 6(3):223-34. PubMed ID: 11052177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological activities of lipopolysaccharides of Proteus spp. and their interactions with polymyxin B and an 18-kDa cationic antimicrobial protein (CAP18)-derived peptide.
    Swierzko AS; Kirikae T; Kirikae F; Hirata M; Cedzynski M; Ziolkowski A; Hirai Y; Kusumoto S; Yokochi T; Nakano M
    J Med Microbiol; 2000 Feb; 49(2):127-138. PubMed ID: 10670563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.